Compared with placebo-treated participants, omega-3 polyunsaturated fatty acids (omega-3 PUFAs) intake could improve ALT (SMD, −0.50; −0.88, −0.11), AST (SMD, −0.54; −1.04, −0.05), GGT (SMD, −0.48; −0.64, −0.31), HOMA-IR (SMD, −0.40; −0.58, −0.22), glucose (SMD, −0.25; −0.43, −0.06), and TG (SMD,-0.47; −0.76, −0.19) in patients with NAFLD [62]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.